> Detailanzeige
Stocker, Gertraud
[VerfasserIn];
Lorenzen, Sylvie
[VerfasserIn];
Ettrich, Thomas J.
[VerfasserIn];
Herz, Anne-Lina
[VerfasserIn];
Longo, Federico
[VerfasserIn];
Kiani, Alexander
[VerfasserIn];
Venerito, Marino
[VerfasserIn];
Trojan, Jörg
[VerfasserIn];
Mahlberg, Rolf
[VerfasserIn];
Moosmann, Nicolas
[VerfasserIn];
Chibaudel, Benoist
[VerfasserIn];
Kubicka, Stefan
[VerfasserIn];
Greil, Richard
[VerfasserIn];
Daum, Severin
[VerfasserIn];
Geißler, Michael
[VerfasserIn];
Larcher-Senn, Julian
[VerfasserIn];
Keller, Gisela
[VerfasserIn];
Lordick, Florian
[VerfasserIn];
Haag, Georg Martin
[VerfasserIn]
S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma
: final results of the randomized AIO MATEO phase II trial
Teilen
Literatur-
verwaltung
Direktlink
Zur
Merkliste
Lösche von
Merkliste
Per Email teilen
Auf Twitter teilen
Auf Facebook teilen
Per Whatsapp teilen
- Medientyp: E-Artikel
- Titel: S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma : final results of the randomized AIO MATEO phase II trial
- Beteiligte: Stocker, Gertraud [VerfasserIn]; Lorenzen, Sylvie [VerfasserIn]; Ettrich, Thomas J. [VerfasserIn]; Herz, Anne-Lina [VerfasserIn]; Longo, Federico [VerfasserIn]; Kiani, Alexander [VerfasserIn]; Venerito, Marino [VerfasserIn]; Trojan, Jörg [VerfasserIn]; Mahlberg, Rolf [VerfasserIn]; Moosmann, Nicolas [VerfasserIn]; Chibaudel, Benoist [VerfasserIn]; Kubicka, Stefan [VerfasserIn]; Greil, Richard [VerfasserIn]; Daum, Severin [VerfasserIn]; Geißler, Michael [VerfasserIn]; Larcher-Senn, Julian [VerfasserIn]; Keller, Gisela [VerfasserIn]; Lordick, Florian [VerfasserIn]; Haag, Georg Martin [VerfasserIn]
- Erschienen: 2 June 2023
- Erschienen in: ESMO open ; 8(2023), 3 vom: Juni, Artikel-ID 101572, Seite 1-9
- Sprache: Englisch
- DOI: 10.1016/j.esmoop.2023.101572
- ISSN: 2059-7029
- Identifikator:
- Schlagwörter: chemotherapy ; esophageal cancer ; esophagogastric adenocarcinoma ; gastric cancer ; maintenance ; S-1
- Entstehung:
-
Anmerkungen:
Interim results of this trial have been presented at ESMO Congress 2020 and DGHO Congress 2020
- Beschreibung: Purpose - Platinum-fluoropyrimidine combinations are standard of care for treatment of metastatic esophagogastric adenocarcinoma. The optimal duration of first-line chemotherapy is unknown, however, and maintenance strategies have not yet been established. - Design - MATEO is an international randomized phase II trial exploring efficacy and safety of S-1 maintenance therapy in human epidermal growth factor receptor 2 (HER2)-negative advanced esophagogastric adenocarcinoma. After 3 months of first-line platinum-fluoropyrimidine-based induction therapy, patients without progression were randomized in a 2 : 1 allocation to receive S-1 monotherapy (arm A) or to continue combination chemotherapy (arm B). The primary objective was to show non-inferiority of overall survival in the S-1 maintenance group. Progression-free survival, adverse events, and quality of life were secondary endpoints. - Results - From 2014 to 2019, 110 and 55 patients were randomized in arm A and arm B, respectively (recruitment closed prematurely). Median overall survival from randomization was 13.4 months for arm A and 11.4 months for arm B [hazard ratio 0.97 (80% confidence interval 0.76-1.23), P = 0.86]. Median progression-free survival from randomization was 4.3 and 6.1 months for arm A versus arm B, respectively [hazard ratio 1.10 (80% confidence interval 0.86-1.39), P = 0.62]. Patients in arm A had numerically fewer treatment-related adverse events (84.9% versus 93.9%) and significantly less peripheral sensory polyneuropathy ≥grade 2 (9.4% versus 36.7%). - Conclusions - S-1 maintenance following platinum-based induction therapy leads to non-inferior survival outcomes compared with the continuation of platinum-based combination. Toxicity patterns favor a fluoropyrimidine maintenance strategy. These data challenge the continued use of platinum combination chemotherapy after response to 3 months induction therapy in patients with advanced human epidermal growth factor receptor 2-negative esophagogastric adenocarcinoma.
- Zugangsstatus: Freier Zugang